HADCORP

Home

Implant Research

Dr Ostermeyer's Research

Neoplasms & Implants

Platinum Testing

Children and Silicone

About Breast Implants

Alternative Implants

Suicide and Implants

Implants and the FDA

Implants in the UK

Silicone Immune Protocol

Biotoxins

MCS

Implant Identification

Implant Photos

Orthopaedic Implants

Board of Directors

Medical Device News

Glossary

Implant Resources

Contact Us

Members
 

Knowledge Empowers   


Long-Distance Retrograde Effects of Botulinum Neurotoxin A

 

The Journal of Neuroscience, April 2, 2008, 28(14):3689-3696; doi:10.1523/JNEUROSCI.0375-08.2008

 

Flavia Antonucci,1 Chiara Rossi,1 Laura Gianfranceschi,2 Ornella Rossetto,3 and Matteo Caleo1

1Istituto di Neuroscienze, Consiglio Nazionale delle Ricerche, and 2Scuola Normale Superiore, 56100 Pisa, Italy, and 3Dipartimento di Scienze Biomediche, Università di Padova, 35121 Padova, Italy

Correspondence should be addressed to Dr. Matteo Caleo, Istituto di Neuroscienze, Consiglio Nazionale delle Ricerche, via G. Moruzzi 1, 56100 Pisa, Italy. Email: caleo@in.cnr.it

Botulinum neurotoxins (designated BoNT/A–BoNT/G) are bacterial enzymes that block neurotransmitter release by cleaving essential components of the vesicle fusion machinery. BoNT/A, which cleaves SNAP-25 (synaptosomal-associated protein of 25 kDa), is extensively exploited in clinical medicine to treat neuromuscular pathologies, facial wrinkles, and various types of pain. It is widely assumed that BoNT/A remains at the synaptic terminal and its effects are confined to the injection site. Here we demonstrate that catalytically active BoNT/A is retrogradely transported by central neurons and motoneurons and is then transcytosed to afferent synapses, in which it cleaves SNAP-25. SNAP-25 cleavage by BoNT/A was observed in the contralateral hemisphere after unilateral BoNT/A delivery to the hippocampus. Appearance of cleaved SNAP-25 resulted in blockade of hippocampal activity in the untreated hemisphere. Injections of BoNT/A into the optic tectum led to the appearance of BoNT/A-truncated SNAP-25 in synaptic terminals within the retina. Cleaved SNAP-25 also appeared in the facial nucleus after injection of the toxin into rat whisker muscles. Experiments excluded passive spread of the toxin and demonstrated axonal migration and neuronal transcytosis of BoNT/A. These findings reveal a novel pathway of BoNT/A trafficking in neurons and have important implications for the clinical uses of this neurotoxin.

Key words: synaptic transmission; SNAP-25; retrograde axonal transport; transcytosis; hippocampus; visual system

Received Sept. 19, 2007; accepted Feb. 13, 2008.

Correspondence should be addressed to Dr. Matteo Caleo, Istituto di Neuroscienze, Consiglio Nazionale delle Ricerche, via G. Moruzzi 1, 56100 Pisa, Italy. Email: caleo@in.cnr.it





Implant Research


The information on this website is presented for educational purposes by the Human Adjuvant Disease Corp.